SRRK Maintained by Evercore ISI Group -- Price Target Raised to
Evercore ISI Group analyst Cory Kasimov maintained an 'Outperform' rating on Scholar Rock Holding Corp (SRRK) and raised the price target from $65.00 to $72.00, a 10.77% increase. SRRK's current price is $47.34 with a market cap of $5.77 billion. The company's GF Score™ is 29/100, indicating room for improvement in financial metrics. Insider activity shows $923,107 in sales over the last three months. The company focuses on biotechnology, developing therapies for rare neuromuscular diseases.
How this was made
The 30-second read
Why it matters
The PT raise may prompt short‑term buying, but fundamentals remain weak.
Market read
Rating upgrade could generate modest buying pressure for SRRK and similar biotech stocks.
What to watch
Insider sales of $923k and a GF score of 29 suggest underlying concerns.
Background
Analyst rating updates influence investor expectations and can trigger price moves.
Ticker impact
Evercore ISI raised Scholar Rock Holding Corp (SRRK) price target to $72 from $65, maintaining an Outperform rating.
Potential short-term price rally toward the new $72 target.
The 10% PT increase reflects improved outlook, but low GF score and high P/S ratio temper expectations.
Market effects
May lift sentiment for biotech peers focused on rare disease therapies.
Limited to US biotech sector.
Modest, as SRRK is a mid‑cap US biotech.
Counterpoint
High valuation metrics and low profitability could limit upside despite the rating lift.
Key entities
- analyst_firmEvercore ISI Group
Provided the rating and price target update.
- companyScholar Rock Holding Corp
Biotech firm focused on rare neuromuscular diseases.
